Skip to main content
. 2016 Sep 14;5(10):2965–2976. doi: 10.1002/cam4.850

Table 5.

Hazards Ratio (HR) for Alzheimer's disease (AD) after first primary cancer diagnosis, 1992–2005a

<1 year follow‐up 1–<5 year follow‐up 5–<10 year follow‐up 0–<10 year follow‐up
HR 95% CI HR 95% CI HR 95% CI Controlb(n) Caseb(n) HR 95% CI
Overall 0.99 0.84–1.17 0.77 0.72–0.83 0.89 0.84–0.95 9714 11812 0.87 0.84–0.90
Sex
Men 1.02 0.80–1.29 0.79 0.72–0.88 0.83 0.76–0.92 3126 6350 0.90 0.85–0.95i
Women 0.96 0.76–1.21 0.75 0.68–0.82 0.94 0.86–1.03 6588 5462 0.84 0.80–0.88i
Race
White 0.97 0.81–1.17 0.75 0.70–0.81 0.90 0.84–0.97 8160 10081 0.86 0.83–0.89i
Non‐white 1.35 0.98–1.85 0.94 0.81–1.10 0.90 0.77–1.06 1554 1731 0.96 0.88–1.04
Age at cancer diagnosis, (years)
66–<70 1.25 0.91–1.71 0.70 0.61–0.80 0.96 0.86–1.08 3665 1338 0.90 0.84–0.97
70–<80 0.87 0.70–1.09 0.79 0.72–0.86 0.87 0.81–0.94 8389 8193 0.87 0.83–0.90i
80–<84 1.05 0.75–1.49 0.78 0.66–0.91 – – 3584 2281 0.85 0.79–0.91i
Smoking‐related cancersc 1.14 0.91–1.41 0.83 0.74–0.93 0.91 0.80–1.03 9714 2286 0.91 0.86–0.96i
Non‐smoking‐related cancersd 0.97 0.81–1.16 0.77 0.71–0.82 0.90 0.84–0.96 9714 9526 0.86 0.83–0.89i
Individual cancer sites
Oral cavitye 1.30 0.83–2.05 0.65 0.47–0.91 0.63 0.38–1.05 9714 105 0.83 0.68–1.01
Esophageal 1.26 0.74–2.17 0.69 0.40–1.20 0.43 0.11–1.72 9714 44 0.93 0.69–1.26
Stomach 0.91 0.53–1.55 0.83 0.60–1.16 0.98 0.60–1.58 9714 100 0.83 0.67–1.02
Small intestine 0.57 0.21–1.60 0.78 0.46–1.35 0.47 0.15–1.47 9714 25 0.68 0.46–1.02
Colon 1.23 0.94–1.61 0.85 0.74–0.97 0.92 0.79–1.07 9714 1256 0.92 0.86–0.99
Rectumf 1.16 0.82–1.66 0.55 0.44–0.69 0.93 0.73–1.18 9714 370 0.79 0.71–0.89i
Pancreas 0.66 0.39–1.11 0.35 0.17–0.72 0.53 0.13–2.18 9714 45 0.68 0.50–0.92
Larynx 0.61 0.29–1.27 0.68 0.47–0.97 0.74 0.45–1.20 9714 73 0.72 0.57–0.92
Lung and bronchus 1.10 0.84–1.44 0.88 0.75–1.03 0.96 0.77–1.20 9714 791 0.96 0.88–1.04
Melanomag 0.79 0.49–1.26 0.76 0.60–0.96 0.89 0.68–1.17 8160 303 0.82 0.71–0.93
Breast (female) 0.84 0.62–1.13 0.77 0.68–0.87 0.98 0.87–1.10 6588 2187 0.88 0.83–0.94i
Cervix 1.94 0.85–3.93 1.01 0.65–1.57 1.25 0.70–2.21 6588 64 1.30 1.00–1.69
Uterush 1.04 0.68–1.58 0.63 0.50–0.78 0.84 0.67–1.05 6588 385 0.80 0.71–0.90i
Ovary 0.60 0.32–1.12 0.31 0.21–0.47 1.19 0.77–1.81 6588 89 0.58 0.46–0.72i
Prostate 0.92 0.62–1.22 0.83 0.74–0.93 0.86 0.77–0.96 3126 3574 0.90 0.85–0.96i
Urinary bladder 1.09 0.79–1.49 0.88 0.75–1.03 0.95 0.79–1.14 9714 779 0.97 0.89–1.06
Kidney/renal 1.27 0.85–1.89 0.79 0.62–1.00 0.84 0.61–1.14 9714 243 0.83 0.72–0.96
Thyroid 0.69 0.34–1.41 0.56 0.36–0.86 0.87 051–1.46 9717 57 0.71 0.54–0.94
Leukemia 0.79 0.50–1.26 0.64 0.48–0.84 0.71 0.48–1.05 9714 163 0.72 0.61–0.85i
a

Models have been adjusted for race, sex and number of doctors' visits, stratified on birth year and cancer registry area, except that sex was not adjusted for in the subpopulation based on sex, nor race, in the subpopulation defined by race. There were a total of 742,809 cancer patients and 420,518 persons in the comparison population. Data source is SEER‐Medicare. Cancers were classified using the “SEER site recode with Kaposi sarcoma and mesothelioma.” Refer to http://seer.cancer.gov and for details, see site recode ICD‐O‐3.

b

Number of AD cases.

c

Smoking‐related cancers include oral cavity and pharynx, lip, pancreas, lung and bronchus, larynx, cervix, kidney and renal pelvis, bladder, esophagus, and stomach.

d

Non‐smoking‐related cancers include all cancers other than smoking‐related cancers.

e

Includes tongue, floor of mouth, gum and mouth, tonsil, oropharynx, hypopharynx.

f

Includes rectum and rectosigmoid junction.

g

Only whites.

h

Includes corpus uterine and uterus, not otherwise specified.

i

P‐values for the associations between the groups (e.g., men) and specific cancer sites with PD (for 0 < 10 years) that were statistically significant after multiple comparison corrections (n = 28 comparisons) at a level of P < 0.0018).